Biotech stocks Jaguar Health and Viking Therapeutics saw sharp declines on Wednesday, though both remain up significantly over the past month, suggesting individual profit-taking rather than a broader market trend.
Jaguar Health collapsed 59% on no verified catalyst, likely profit-taking after a sharp prior run, with the stock still up 9% over the past month.
Viking Therapeutics slipped 4% as a pullback after positive obesity trial data, with the stock up 14% over the past month and a special investor call scheduled.
Jaguar Health shares collapsed 59% on Wednesday, likely due to profit-taking following a recent rally, while Viking Therapeutics retreated 4% after positive obesity trial data. Both moves appear to be company-specific, as the broader iShares Biotechnology ETF remained largely unchanged, signaling no sector-wide selloff.
No, the iShares Biotechnology ETF (IBB) remained nearly flat during the session, suggesting the declines are company-specific rather than a broader sector selloff.